Automata Raises $45M to Power AI‑Ready Lab Automation with Danaher Backing

The numbers behind the business are also starting to look serious. Automata is already working with five major pharmaceutical companies and has been involved in some of the largest lab automation programs in the industry. Much of this growth comes from repeat deployments, as teams roll out the platform across multiple sites once the first lab proves its value. When a lab can run more experiments in less time, with better data quality and fewer errors, it becomes easier to justify expanding that model across an entire network.​

Danaher’s involvement takes the story a step further. Through Danaher Ventures’ participation in the round, the two companies are setting up a strategic partnership that links Automata’s automation stack with Danaher’s portfolio of instruments, reagents, and software. Technologies from Danaher businesses such as Molecular Devices and Beckman Coulter Life Sciences are expected to integrate Automata’s software, enabling more complete “lab‑in‑a‑box” style solutions. For labs under pressure to speed up discovery while holding down costs, this kind of tight integration can remove a lot of custom engineering and one‑off scripting.

There is also a cultural shift happening in how scientists think about automation. In older setups, researchers often had to “program the robot” directly, learning vendor‑specific interfaces or relying on specialists. Automata’s approach flips that around by letting scientists focus on programming the experiment instead. The platform takes care of translating those workflows into coordinated steps across robots and instruments. That not only makes automation more accessible, it also lowers the barrier for teams that might not have deep coding expertise in‑house.​

With the new capital, Automata plans to scale both its technology and its reach. The Series C funding will accelerate platform development, from software orchestration and data infrastructure to support for new instrument types and workflows. It will also help the company keep up with rising demand from pharma and biotech customers that want to redesign their labs around higher throughput, better reproducibility, and tighter links to AI pipelines.

For futureTEKnow readers who track how automation is reshaping industries, Automata is a good example of a company sitting right at the crossroads of robotics, software, and life sciences. Its latest round is more than just another funding headline. It signals growing conviction that the next generation of drug discovery and biological research will depend on labs that can operate like programmable platforms, not manual workshops. If Automata can keep executing on that vision, the humble wet lab might soon feel as programmable as the code that drives it.